IPO Profile: Seres Therapeutics Inc

The company, which focuses on debilitating infection of the colon, raised a $133.7 million IPO

1 July 2015•1 min read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.